Mr McCann has board experience with some of Australia's companies. He is Chairman of China Matters and a member of Champions of Change, a ProChancellor of the University of Sydney, and a Trustee of the Sydney Opera House Trust. Previously, Kevin has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited and ING Management Limited. Kevin practiced as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He is chair of the people, culture and a member of the risk committee.

Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She is an independent non-executive director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk & Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. She is Chair of the risk committee and a member of the people, culture and disclosure committee.

Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre).

Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX CRO, a full service CRO for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH, manufacturers of radiopharmaceutical precursors globally. Andreas is further Founder, General Manager and Medical Director for Therapeia, an early-stage development company in the field of neurooncology, which was acquired by Telix. Andreas has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of numerous patents and publications in the field of Nuclear Medicine, neurology, infection and immunology.

Mr Buck has spent his professional career in a range of entrepreneurial and management positions in industrial companies. He has served as founder and Managing Director of range of companies in the fields of manufacturing, technology, demilitarisation, pharmaceuticals and information technologies. He is the co-founder of ITM Isotopen Technologien Munchen AG. Since 2012, he has acted as senior advisor to the CEO in a role that continues to support the ITM group as it has become a leader in next generation medical isotopes and theranostics. He is a member of the Risk, People and culture committee.

Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. He is Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects, Director of The Mindgardens Neuroscience Network, and serves as a Governor of the Florey Neurosciences Institute. Previously he was a Director of The Howard Florey Institute of Experimental Physiology and Medicine, and served on the Commercialisation Committee of the Florey Institute. He is a member of the Risk, People and culture committee.

Ms Olson has experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health, where she was President of Cardinal Health Nuclear & Precision Health Solutions overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network. Prior to her role at Cardinal Health, Ms Olson served as President of NaviMed and in executive roles at Eli Lilly and Roche, where she attained the position of President and CEO of Roche Diagnostics Corporation. Ms Olson currently serves as a Board member for Castle Biosciences; ERF, Education & Research Foundation for Nuclear Medicine & Molecular Imaging; and is on the Langham Logistics Advisory Board. She was named one of the "10 Best Women Leaders of 2020" by Industry Era and was the first woman to receive the Life Science Alley Luminary Award.

-

-

-

-

-

-

-

-

-

-

-